BiomX Inc. is a clinical stage product discovery company developing natural and engineered phage based therapies to target and kill specific harmful bacteria associated with chronic diseases such as diabetic foot infections. The company uses its proprietary research and development platform to screen identify and combine phage strains that can penetrate biofilms resist resistance and remain stable for manufacturing. Its product candidates are designed to treat conditions…
BiomX Inc. is a clinical stage product discovery company developing natural and engineered phage based therapies to target and kill specific harmful bacteria associated with chronic diseases such as diabetic foot infections. The company uses its proprietary research and development platform to screen identify and combine phage strains that can penetrate biofilms resist resistance and remain stable for manufacturing. Its product candidates are designed to treat conditions where antibiotics have limited efficacy due to resistance or biofilm formation.
BiomX Inc. has not generated any revenue from product sales because all of its candidates remain in clinical development. The company funds its operations through government grants such as the $5.8 million received from the Medical Technology Enterprise Consortium and through private placements including the December 2025 sale of Series Y Convertible Preferred Stock and warrants for gross proceeds of $3.0 million. These financing activities support ongoing research and limited operational activities while the company evaluates strategic alternatives.
BiomX Inc. operates in the highly competitive biotechnology sector focused on phage therapy where it faces rivals such as Locus Biosciences Armata Pharmaceuticals and SNIPR Biome as well as academic programs and larger pharmaceutical companies with greater resources. Its competitive advantages stem from a proprietary phage discovery platform that integrates computational biology microbiology synthetic engineering and high throughput screening to produce optimized phage cocktails or personalized treatments. The company also benefits from collaborations with institutions such as the Walter Reed Army Institute of Research and the National Institutes of Health which provide access to phage libraries and clinical trial support.
The company serves patients suffering from bacterial infections linked to chronic diseases including individuals with diabetic foot infections diabetic foot osteomyelitis and potentially those with cystic fibrosis or atopic dermatitis. Its therapies are intended for use in hospital settings under the supervision of healthcare providers and are being evaluated in clinical trials that enroll adult patients with specific bacterial strains identified through diagnostic testing.